SL-28.

PreclinicalBiologic

SSecond Life Therapeutics

SL-28. is one of 4 biologic programs targeting Head Neck Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Head Neck CancerRecruiting

Head Neck CancerPreclinical

Recruiting

Competition

Competitive Landscape

5 competitors in Head Neck Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

3 2

Taxol

Teva

Phase 2

3 3

Paraplatin

AAvyxa

Phase 2

1 4

SL-28.

SSecond Life Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalRecruiting

Head Neck Cancer

NCT07341737

Clinical

Trials by Indication[1]

Advanced Solid Tumors1 trial

Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors

Available·SSecond Life Therapeutics··NCT06872489

Head Neck Cancer1 trial

A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours

Recruiting·SSecond Life Therapeutics·Preclinical·NCT07341737·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SL-28.. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SL-28. compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SL-28.. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Life Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: SSecond Life Therapeutics

SL-28.

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Advanced Solid Tumors1 trial

Head Neck Cancer1 trial

References

Drug Info

Quick Facts

Related News